Comparison of Cas9 and Cas12a CRISPR editing methods to correct the W1282X-CFTR mutation.
BACKGROUND
W1282X-CFTR variant (c.3846G>A) is the second most common nonsense cystic fibrosis (CF)-causing mutation in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. Even though remarkable breakthroughs have been done towards CF treatment with the approval of four CFTR protein modulators, none of these are approved for patients with nonsense mutations. CRISPR gene editing tools can be of great value to permanently correct the genetic defects caused by these mutations.


METHODS
We compared the capacity of homology-directed repair (HDR) mediated by Cas9 or Cas12a to correct W1282X CFTR mutation in the CFF-16HBEge W1282X CFTR cell line (obtained from CFF), using Cas9/gRNA and Cas12a/gRNA ribonucleoproteins (RNPs) and single strand DNA (ssODN) oligonucleotide donors.


RESULTS
Cas9 shows higher levels of correction than Cas12a as, by electroporating cells with Cas9 RNPs and ssODN donor, nearly 18% of precise editing was achieved compared to just 8% for Cas12a. Such levels of correction increase the abundance of CFTR mRNA and protein, and partially restore CFTR function in the pool of edited cells to 18% of WT CFTR function. Moreover, homozygous corrected clones produced levels of mRNA, protein, and function comparable to those of cells expressing WT CFTR.


CONCLUSION
Altogether, this work demonstrates the potential of gene editing as a therapeutic strategy for CF directly correcting the root cause of the disease.
['Santos|Lúcia|L|', 'Mention|Karen|K|', 'Cavusoglu-Doran|Kader|K|', 'Sanz|David J|DJ|', 'Bacalhau|Mafalda|M|', 'Lopes-Pacheco|Miquéias|M|', 'Harrison|Patrick T|PT|', 'Farinha|Carlos M|CM|']
Cystic fibrosis CFTR W1282X CRISPR/Cas12a CRISPR/Cas9 Human bronchial epithelial cells